Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
With an alcohol by volume figure of 43 percent, the 2-ounce sachets are about as intoxicating as a typical 16-ounce beer, but consumers say that’s just one of their virtues. Kouame claimed they give him a jolt of energy other drinks can’t match — just what he needs to face a long day of hectic traffic, run-ins with police and testy fare negotiations. “It inspires me. It gives me a bit of courage to confront the challenges of life,” he said. From now on, however, Ivory Coast’s government wants Kouame to get his courage elsewhere. Last month, officials announced a ban on alcohol sachets, citing their health risks and the need to combat alcoholism, especially among youth. The measure is one of more than a half-dozen bans or partial bans on alcohol sachets in effect in sub-Saharan Africa, according to the World Health Organization. Other countries with bans include Zambia, Kenya, Tanzania, Rwanda, Burundi, Congo and South Sudan, said Jean-Marie Vianny Maurice Yameogo, the WHO’s Ivory Coast representative. Tracking the sales of alcohol sachets, many containing spirits distilled from palm wine, is difficult because they are often produced outside regulated markets. The sachets are typically mass-produced in West Africa, with colorful packaging. The drink “Amour Profond,” or “Deep Love,” shows a man standing behind a bare-shouldered woman, whispering into her ear. The sachets are not necessarily more potent than other drinks available. Palm wine-based traditional drinks such as koutoukou, which are similarly cheap, can have alcohol by volume rates of more than 50 percent. But sachets are more likely to contain toxic chemicals such as methanol, or wood alcohol, Yameogo said. And the packaging often boasts of health and other benefits that Yameogo said have no basis in science. Some are said to provide cures for maladies such as hemorrhoids, while others are reputed to function as appetite-suppressants or aphrodisiacs. Moreover, the small sachets are easy to hide, making them especially tempting for schoolchildren, according to the Ivorian government and the WHO. “It’s something that’s accessible to everyone. You can buy a sachet, put it in your pocket and just walk around like that,” said Patrick Gbodou, president of School Anti-Drug, an Ivorian organization that campaigns against drinking and drug use by students. The official drinking age in Ivory Coast is 21, but it is rarely enforced, and teenage drinking is common. Vendors are worried they will take a huge hit if the ban on sachets is enforced, as many drinkers go for sachets and nothing else. “The government needs to have pity on us,” said Adjo Abega, the owner of a bar in Abidjan’s Port-Bouet district. Drinkers generally acknowledge the health risks posed by alcohol sachets, but some criticized the government for cracking down on their favorite vice while permitting other health hazards such as cigarettes. Desire N’Guessan, an unemployed 26-year-old, began drinking sachets when he was a teenager. He said he relies on them to ward off illness and for motivation to keep looking for work. “When you are not able to overcome your timidity, it can be difficult to operate in your neighborhood,” N’Guessan said. If the government makes good on the ban, he warned, Ivorian children could turn to drugs. He also predicted marches and protests. But Kouame, the taxi driver, was less worried. In the absence of alcohol sachets, he said he would switch up his morning routine by drinking glasses of palm wine instead, adding: “Man can adapt to anything.”

Ex Output:
Ivory Coast is latest to crack down on alcohol sachets.


Ex Input:
Entitled “Beyond The Physical: A Symposium on Mental Health in Sports,” the forum will feature a series of panels with current and former NFL players as well as mental health organizations, caregivers, medical providers and media personalities. The aim is to raise awareness of mental health and promote a culture in which people, including athletes, are encouraged to seek help and support to achieve overall wellness. Confirmed panelists include NFL wide receiver and co-founder of Project 375 Brandon Marshall;  former NFL cornerback Asher Allen; former Pro Bowl running back Warrick  Dunn; Atlanta Falcons senior director of player affairs Kevin Winston; and representatives from Active Minds, Mental Health America (MHA) of Georgia, the American Psychological Association, and Campaign to Change Direction. “May is Mental Health Awareness Month and the NFL is pleased to partner with the NFLPA and Cigna to increase awareness and decrease the stigma around mental health ...” said Dwight Hollier, the NFL’s vice president of wellness and clinical services. “This effort is especially important in light of the messages young athletes receive about toughness and the need to be strong all the time. Through our discussions with caregivers, athletes, professionals and others, we will shine a light on mental health in sports and discuss ways to support athletes and others on the journey toward total wellness.” ___ For more NFL coverage: http://www.pro32.ap.org and http://www.twitter.com/AP_NFL

Ex Output:
NFL, union to host symposium on mental health on May 14.


Ex Input:
The article is silent on the price of Rituxan. Since the company is investing a significant sum to research an additional use, the price is worth mentioning. The article does a good job of sketching the benefits shown in this research. Focusing on the clinical endpoint of relapse, and using percentages of relapse with the drug and the placebo, makes it easy for readers to understand. The article explores the issue of whether Rituxan may suppress the immune response too much, making the patient vulnerable to other diseases. It also explains how this effect has been observed in the drug Tysabri, a different immune suppressant used for MS. This article is based on published results of a Phase II trial published in the New England Journal of Medicine. The news article does a decent job emphasizing the preliminary nature of the findings, and that larger trials are needed to ensure safety, efficacy and long-term benefits. The article does nothing to exaggerate the severity or consequences of MS. The reporter draws on the journal article and the accompanying editorial. Sources interviewed include the primary author, one medical expert representing the National Multiple Sclerosis Society and one clinician who treated some patients in the study but was not an author. This is sufficient sourcing. It is worth pointing out here, however, that Genentech and Biogen Idec, makers of Rituxan, are “Corporate Star” supporters of the National Multiple Sclerosis Society. The article states that six other drugs, all with shortcomings, are available to treat relapsing-remitting MS. The article makes clear that the drug is currently on the market and approved for other uses. But it did not state whether Rituxan is, or may become, used off-label for relapsing-remitting MS. And, as noted in our summary comment below, there are issues surrounding off-label use that could have been addressed. The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research. There is no evidence the article draws from a press release.

Ex Output:

MS therapy shows promise in test